NCT01137435已完成4 期
Regulatory Post-Marketing Surveillance (PMS) Study for ADACEL™ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult)
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 659
- 试验地点
- 2
- 主要终点
- Summary of Adverse Events Reported in Participants That Received a Single Intramuscular Dose of Adacel™
研究概览
简要总结
This safety surveillance study is being conducted in accordance with Korea Food and Drug Administration (KFDA) Notification No. 2009-46 "Basic standard for reexamination of new drug".
The study objective is to assess within 30 days post-administration, the safety of ADACEL™ administered under the real clinical practice.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 11 Years 至 64 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Summary of Adverse Events Reported in Participants That Received a Single Intramuscular Dose of Adacel™
时间窗: 30 days post-vaccination
All adverse event reported by vaccinated subjects within 30 days post-vaccination during the 6 year post marketing surveillance period.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)Hepatitis ANCT01838070Sanofi Pasteur, a Sanofi Company614
已完成
不适用
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast CancerBreast CancerNCT01047358Pfizer206
已完成
不适用
A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox CapsuleSchizophreniaBipolar DisorderNCT01053429Pfizer's Upjohn has merged with Mylan to form Viatris Inc.3,391
进行中（未招募）
不适用
Iclusig PMS in CML or Ph+ALL PatientsChronic Myeloid LeukemiaPhiladelphia Chromosome-positive Acute Lymphoblastic LeukemiaNCT03709017Korea Otsuka Pharmaceutical Co., Ltd.50
撤回
不适用
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and NeckNeoplasms, Squamous CellNCT01075841Merck KGaA, Darmstadt, Germany